Equities

Lyka Labs Ltd

LYKALABS:NSI

Lyka Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)149.02
  • Today's Change2.02 / 1.37%
  • Shares traded100.27k
  • 1 Year change+34.25%
  • Beta1.4076
Data delayed at least 15 minutes, as of Sep 20 2024 11:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments82143188
Total Receivables, Net314202185
Total Inventory967082
Prepaid expenses2.58----
Other current assets, total122867
Total current assets507442522
Property, plant & equipment, net688637856
Goodwill, net1.99----
Intangibles, net117207261
Long term investments0.75163144
Note receivable - long term1885660
Other long term assets641013
Total assets1,5671,5151,856
LIABILITIES
Accounts payable12194120
Accrued expenses5.04----
Notes payable/short-term debt10179671
Current portion long-term debt/capital leases45138.33
Other current liabilities, total104140194
Total current liabilities376326994
Total long term debt442659625
Total debt5887511,304
Deferred income tax384042
Minority interest1.112.301.53
Other liabilities, total283461
Total liabilities8861,0611,723
SHAREHOLDERS EQUITY
Common stock331307287
Additional paid-in capital1,544----
Retained earnings (accumulated deficit)(1191)148(154)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(2.93)----
Total equity682454133
Total liabilities & shareholders' equity1,5671,5151,856
Total common shares outstanding333129
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.